Skip to content
Peptigraph home

Ecnoglutide: Trials and FDA Status

Ecnoglutide is a glp-1 agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated

Where it stands

US status
Investigational
Phase
Phase 3
Sponsor
Hangzhou Sciwind Biosciences
Expected FDA decision
None announced
no primary source states a date (checked 2 Oct 2026)
Trial IDs (NCT)
NCT05111912, NCT05813795, NCT05680155, NCT05680129
Results

Reported results

  • 2025Phase 3 in Chinese adults with overweight or obesity (Lancet Diabetes Endocrinol 2025): weight change at week 40“At week 40, the least-squares mean percentage change in bodyweight was -9·1% (SE 0·8) in the ecnoglutide 1·2 mg group, -10·9% (0·9) in the ecnoglutide 1·8 mg group, and -13·2% (0·8) in the ecnoglutide 2·4 mg group versus 0·1% (0·8) in the placebo group”pubmed.ncbi.nlm.nih.gov
  • 2026Phase 3 in type 2 diabetes (2026): HbA1c change at week 24“At week 24, the least squares mean changes from baseline in HbA1c were -1.96% (95% CI -2.18 to -1.73) with ecnoglutide 0.6 mg and -2.43% (95% CI -2.65 to -2.20) with ecnoglutide 1.2 mg versus -0.87% (-1.09 to -0.65) with placebo.”pubmed.ncbi.nlm.nih.gov

Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.

Timeline

Milestones

  1. Published in Nature communications (2026): Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
  2. Review in Drugs (2026) reports first approvals of ecnoglutide in China: type 2 diabetes (January 2026) and long-term weight management (March 2026)
  3. Published in The lancet. Diabetes & endocrinology (2025): Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
  4. Published in The lancet. Diabetes & endocrinology (2025): Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
  5. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): primary completion
  6. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): primary completion
  7. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): primary completion
  8. Published in Nature communications (2024): Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
  9. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): first posted on ClinicalTrials.gov
  10. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): study start
  11. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): first posted on ClinicalTrials.gov
  12. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): first posted on ClinicalTrials.gov
  13. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): study start
  14. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): study start
  15. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): primary completion
  16. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): study start
  17. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): first posted on ClinicalTrials.gov

What people search

  • ecnoglutide phase 310/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity (NCT05111912)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (NCT05813795)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  3. 3A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (NCT05680155)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  4. 4A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (NCT05680129)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  5. 5Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.Nature communications · 2024PMID 39333121Accessed 2 Oct 2026
  6. 6Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.The lancet. Diabetes & endocrinology · 2025PMID 40555243Accessed 2 Oct 2026
  7. 7Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.The lancet. Diabetes & endocrinology · 2025PMID 40854315Accessed 2 Oct 2026
  8. 8Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.Nature communications · 2026PMID 41501026Accessed 2 Oct 2026
  9. 9Ecnoglutide: First Approvals.Drugs · 2026PMID 42412371Accessed 2 Oct 2026

Found an error? Report a correction.